Botulinum neurotoxin type a for the treatment of benign prostatic hyperplasia: Randomized study comparing two doses

The Scientific World Journal

Volumn 2012, Issue , 2012, Pages

  Arnouk, René ^a   Bellucci, Carlos Henrique Suzuki ^b   Stull, Roberto Benatuil ^a   De Bessa Junior, José ^c   Malave, Cesar Augusto ^a   Gomes, Cristiano Mendes ^d  

^a Hospital Militar Dr Carlos Arvelo   (Venezuela)

^b Uroclínica de Joinville ^*  (Brazil)

^c DEPARTAMENTO DE CIÊNCIAS BIOLÓGICAS   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BOTULINUM TOXIN A; PROSTATE SPECIFIC ANTIGEN; KALLIKREIN; KALLIKREIN RELATED PEPTIDASE 3, HUMAN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN;

AGED; ARTICLE; BLADDER IRRIGATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FLOW RATE; FOLEY BALLOON CATHETER; HEMATURIA; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; POST VOID RESIDUAL VOLUME; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; PROSTATE VOLUME; PROSTATITIS; RANDOMIZED CONTROLLED TRIAL; RENAL SYSTEM PARAMETERS; TRANSURETHRAL RESECTION; TREATMENT FAILURE; URINE RETENTION; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; INJECTION; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROSTATE; TREATMENT OUTCOME; URINALYSIS;

AGED; BOTULINUM TOXINS, TYPE A; HUMANS; INJECTIONS; KALLIKREINS; MALE; MIDDLE AGED; ORGAN SIZE; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; TREATMENT OUTCOME; URINALYSIS;

EID: 84867806302     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/2012/463574     Document Type: Article

References (28)

1. Barry M. J., Roehrborn C. G., Extracts from clinical evidence: benign prostatic hyperplasia. British Medical Journal 2001 323 7320 1042 1046 2-s2.0-0035802581 (Pubitemid 33042304)
2. Clifford G. M., Farmer R. D. T., Medical therapy for benign prostatic hyperplasia: a review of the literature. European Urology 2000 38 1 2 19 2-s2.0-0034047484 (Pubitemid 30418009)
3. Oesterling J. E., Benign prostatic hyperplasiamedical and minimally invasive treatment options. The New England Journal of Medicine 1995 332 2 99 109 2-s2.0-0028887712 10.1056/NEJM199501123320207
4. de La Rosette J. J. M. C. H., Alivizatos G., Madersbacher S., Perachino M., Thomas D., Desgrandchamps F., De Wildt M., EAU guidelines on Benign Prostatic Hyperplasia (BPH). European Urology 2001 40 3 256 264 2-s2.0-0035742943 10.1159/000049784 (Pubitemid 34701895)
5. Lepor H., Williford W. O., Barry M. J., Brawer M. K., Dixon C. M., Gormley G., Haakenson C., Machi M., Narayan P., Padley R. J., The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. The New England Journal of Medicine 1996 335 8 533 539 2-s2.0-9444268678 10.1056/ NEJM199608223350801 (Pubitemid 26272307)
6. McConnell J. D., Barry M. J., Bruskewitz R. C., Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research. Clinical Practice Guideline 1994 8 1 17 2-s2.0-0028372124
7. McConnell J. D., Bruskewitz R., Walsh P., Andriole G., Lieber M., Logan Holtgrewe H., Albertsen P., Roehrborn C. G., Nickel J. C., Wang D. Z., Taylor A. M., Waldstreicher J., The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. The New England Journal of Medicine 1998 338 9 557 563 2-s2.0-0006075228 10.1056/NEJM199802263380901 (Pubitemid 28114643)
8. Narayan P., Lepor H., Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology 2001 57 3 466 470 2-s2.0-0035123154 10.1016/S0090-4295(00)01042-6 (Pubitemid 32192976)
9. Lu-Yao G. L., Barry M. J., Chang C. H., Wasson J. H., Wennberg J. E., Cockett A. T. K., Holtgrewe H. L., Transurethral resection of the prostate among medicare beneficiaries in the United States: time trends and outcomes. Urology 1994 44 5 692 699 2-s2.0-0028673062 10.1016/S0090-4295(94)80208-4
10. Dykstra D. D., Sidi A. A., Scott A. B., Pagel J. M., Goldish G. D., Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. Journal of Urology 1988 139 5 919 922 2-s2.0-0023909940
11. Lim S. K., Quek P. L. C., Intraprostatic and bladder-neck injection of botulinum A toxin in treatment of males with bladder-neck dyssynergia: a pilot study. European Urology 2008 53 3 620 627 2-s2.0-38749090600 10.1016/j.eururo.2007.10.001 (Pubitemid 351179004)
12. Schurch B., De Sèze M., Denys P., Chartier-Kastler E., Haab F., Everaert K., Plante P., Perrouin-Verbe B., Kumar C., Fraczek S., Brint M. F., Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. Journal of Urology 2005 174 1 196 200 2-s2.0-20444459051 10.1097/01.ju.0000162035.73977.1c (Pubitemid 40825713)
13. Schurch B., Stöhrer M., Kramer G., Schmid D. M., Gaul G., Hauri D., Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. Journal of Urology 2000 164 3, part 1 692 697 2-s2.0-0033870343 (Pubitemid 30637604)
14. Apostolidis A., Popat R., Yiangou Y., Cockayne D., Ford A. P. D. W., Davis J. B., Dasgupta P., Fowler C. J., Anand P., Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. Journal of Urology 2005 174 3 977 982 2-s2.0-23744514242 10.1097/01.ju.0000169481.42259.54 (Pubitemid 41140654)
15. Maria G., Brisinda G., Civello I. M., Bentivoglio A. R., Sganga G., Albanese A., Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003 62 2 259 264 2-s2.0-0042624721 10.1016/S0090-4295(03)00477-1 (Pubitemid 36952073)
16. Chuang Y. C., Chiang P. H., Huang C. C., Yoshimura N., Chancellor M. B., Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology 2005 66 4 775 779 2-s2.0-26644473667 10.1016/j.urology.2005.04.029 (Pubitemid 41440823)
17. Chuang Y. C., Chiang P. H., Yoshimura N., De Miguel F., Chancellor M. B., Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. British Journal of Urology International 2006 98 5 1033 1037 2-s2.0-33749564739 10.1111/j.1464-410X.2006.06479.x (Pubitemid 44536454)
18. Park D. S., Cho T. W., Lee Y. K., Lee Y. T., Hong Y. K., Jang W. K., Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia. Yonsei Medical Journal 2006 47 5 706 714 2-s2.0-33750695251 10.3349/ymj.2006.47.5.706 (Pubitemid 44697302)
19. Silva J., Silva C., Saraiva L., Silva A., Pinto R., Dinis P., Cruz F., Intraprostatic botulinum toxin type A injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption. European Urology 2008 53 1 153 159 2-s2.0-36448952295 10.1016/j.eururo.2007.08.050 (Pubitemid 350166733)
20. Brisinda G., Cadeddu F., Vanella S., Mazzeo P., Marniga G., Maria G., Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results. Urology 2009 73 1 90 94 2-s2.0-57849094424 10.1016/j.urology.2008.08.475
21. Kuo H. C., Prostate botulinum a toxin injectionan alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 2005 65 4 670 674 2-s2.0-17144393348 10.1016/j.urology.2004.10.077 (Pubitemid 40522997)
22. Chuang Y. C., Tu C. H., Huang C. C., Lin H. J., Chiang P. H., Yoshimura N., Chancellor M. B., Intraprostatic injection of botulinum toxin type- A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs. BMC Urology 2006 6, article 12 2-s2.0-33745410249 10.1186/1471-2490-6-12 (Pubitemid 43941597)
23. de Miguel F., Chancellor M. B., Pittsburgh experience with botulinum toxin A injection. Actas Urologicas Espanolas 2006 30 3 310 314 2-s2.0-33746131935 (Pubitemid 44082218)
24. Doggweiler R., Zermann D. H., Ishigooka M., Schmidt R. A., Botox-induced prostatic involution. Prostate 1998 37 1 44 50 (Pubitemid 28385184)
25. Simpson L. L., Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. Journal of Pharmacology and Experimental Therapeutics 1980 212 1 16 21 2-s2.0-0018906584 (Pubitemid 10131942)
26. MacKenzie I., Burnstock G., Dolly J. O., The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuromuscular transmission. Neuroscience 1982 7 4 997 1006 2-s2.0-0020079880 10.1016/0306-4522(82)90056-2 (Pubitemid 12122249)
27. Chuang Y. C., Huang C. C., Kang H. Y., Chiang P. H., Demiguel F., Yoshimura N., Chancellor M. B., Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland. Journal of Urology 2006 175 3 1158 1163 2-s2.0-32044455310 10.1016/S0022-5347(05)00318-6 (Pubitemid 43200121)
28. Nasu K., Moriyama N., Kawabe K., Tsujimoto G., Murai M., Tanaka T., Yano J., Quantification and distribution of α 1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue. British Journal of Pharmacology 1996 119 5 797 803 2-s2.0-0029860173 (Pubitemid 26366469)